Adaptive T cell immune responses and atherogenesis

Current Opinion in Pharmacology

Volumn 10, Issue 2, 2010, Pages 197-202

  Taleb, Soraya ^a   Tedgui, Alain ^a   Mallat, Ziad ^a  

^a PARIS CARDIOVASCULAR RESEARCH CENTER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 17;

ADAPTIVE IMMUNITY; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; HEART PROTECTION; HUMAN; IMMUNOPATHOGENESIS; INNATE IMMUNITY; MOLECULAR INTERACTION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVIEW; TH1 CELL; TH17 CELL; TH2 CELL;

ADAPTIVE IMMUNITY; ANIMALS; ATHEROSCLEROSIS; DRUG DISCOVERY; HUMANS; INFLAMMATION MEDIATORS; MODELS, IMMUNOLOGICAL; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, HELPER-INDUCER; T-LYMPHOCYTES, REGULATORY;

EID: 77949776151     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2010.02.003     Document Type: Review

References (60)

1. Tedgui A., Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev 2006, 86:515-581.
2. Weber C., Zernecke A., Libby P. The multifaceted contributions of leukocyte subsets to atherosclerosis: lessons from mouse models. Nat Rev Immunol 2008, 8:802-815.
3. Smith J.D., Trogan E., Ginsberg M., Grigaux C., Tian J., Miyata M. Decreased atherosclerosis in mice deficient in both macrophage colony-stimulating factor (op) and apolipoprotein E. Proc Natl Acad Sci U S A 1995, 92:8264-8268.
4. Dansky H.M., Charlton S.A., Harper M.M., Smith J.D. T and B lymphocytes play a minor sole in atherosclerotic plaque formation in the apolipoprotein E-deficient mouse. Proc Natl Acad Sci U S A 1997, 94:4642-4646.
5. -/- mice. J Clin Invest 1997, 100:1575-1580.
6. Robertson A.K., Hansson G.K. T cells in atherogenesis: for better or for worse?. Arterioscler Thromb Vasc Biol 2006, 26:2421-2432.
7. Olofsson P.S., Soderstrom L.A., Wagsater D., Sheikine Y., Ocaya P., Lang F., Rabu C., Chen L., Rudling M., Aukrust P., et al. CD137 is expressed in human atherosclerosis and promotes development of plaque inflammation in hypercholesterolemic mice. Circulation 2008, 117:1292-1301.
8. Krebs P., Scandella E., Bolinger B., Engeler D., Miller S., Ludewig B. Chronic immune reactivity against persisting microbial antigen in the vasculature exacerbates atherosclerotic lesion formation. Arterioscler Thromb Vasc Biol 2007, 27:2206-2213.
9. Mallat Z., Taleb S., Ait-Oufella H., Tedgui A. The role of adaptive T cell immunity in atherosclerosis. J Lipid Res 2009, 50(Suppl):S364-S369.
10. Gupta S., Pablo A.M., Jiang X.C., Wang N., Tall A.R., Schindler C. IFN-gamma potentiates atherosclerosis in apoE knock-out mice. J Clin Invest 1997, 99:2752-2761.
11. -/- mice. Am J Pathol 2000, 157:1819-1824.
12. Whitman S.C., Ravisankar P., Elam H., Daugherty A. T-bet deficiency reduces atherosclerosis and alters plaque antigen-specific immune responses. Proc Natl Acad Sci U S A 2005, 102:1596-1601.
13. Lutgens E., Lievens D., Beckers L., Donners M., Daemen M. CD40 and its ligand in atherosclerosis. Trends Cardiovasc Med 2007, 17:118-123.
14. Lutgens E., Lievens D., Beckers L., Wijnands E., Soehnlein O., Zernecke A., Seijkens T., Engel D., Cleutjens J., Keller A.M., et al. Deficient CD40-TRAF6 signaling in leukocytes prevents atherosclerosis by skewing the immune response toward an antiinflammatory profile. J Exp Med 2010, 207:391-404.
15. King V.L., Cassis L.A., Daugherty A. Interleukin-4 does not influence development of hypercholesterolemia or angiotensin II-induced atherosclerotic lesions in mice. Am J Pathol 2007, 171:2040-2047.
16. -/- mice. Arterioscler Thromb Vasc Biol 2002, 22:456-461.
17. Davenport P., Tipping P.G. The role of interleukin-4 and interleukin-12 in the progression of atherosclerosis in apolipoprotein E-deficient mice. Am J Pathol 2003, 163:1117-1125.
18. Binder C.J., Hartvigsen K., Chang M.K., Miller M., Broide D., Palinski W., Curtiss L.K., Corr M., Witztum J.L. IL-5 links adaptive and natural immunity specific for epitopes of oxidized LDL and protects from atherosclerosis. J Clin Invest 2004, 114:427-437.
19. Miller A.M., Xu D., Asquith D.L., Denby L., Li Y., Sattar N., Baker A.H., McInnes I.B., Liew F.Y. IL-33 reduces the development of atherosclerosis. J Exp Med 2008, 205:339-346.
20. Lewis M.J., Malik T.H., Ehrenstein M.R., Boyle J.J., Botto M., Haskard D.O. Immunoglobulin M is required for protection against atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation 2009, 120:417-426.
21. Mays L.E., Chen Y.H. Maintaining immunological tolerance with Foxp3. Cell Res 2007, 17:904-918.
22. Ait-Oufella H., Salomon B.L., Potteaux S., Robertson A.K., Gourdy P., Zoll J., Merval R., Esposito B., Cohen J.L., Fisson S., et al. Natural regulatory T cells control the development of atherosclerosis in mice. Nat Med 2006, 12:178-180.
23. Mallat Z., Besnard S., Duriez M., Deleuze V., Emmanuel F., Bureau M.F., Soubrier F., Esposito B., Duez H., Fievet C., et al. Protective role of interleukin-10 in atherosclerosis. Circ Res 1999, 85:e17-24.
24. Pinderski L.J., Fischbein M.P., Subbanagounder G., Fishbein M.C., Kubo N., Cheroutre H., Curtiss L.K., Berliner J.A., Boisvert W.A. Overexpression of interleukin-10 by activated T lymphocytes inhibits atherosclerosis in LDL receptor-deficient Mice by altering lymphocyte and macrophage phenotypes. Circ Res 2002, 90:1064-1071.
25. Mallat Z., Gojova A., Marchiol-Fournigault C., Esposito B., Kamate C., Merval R., Fradelizi D., Tedgui A. Inhibition of transforming growth factor-beta signaling accelerates atherosclerosis and induces an unstable plaque phenotype in mice. Circ Res 2001, 89:930-934.
26. Grainger D.J., Mosedale D.E., Metcalfe J.C., Bottinger E.P. Dietary fat and reduced levels of TGFbeta1 act synergistically to promote activation of the vascular endothelium and formation of lipid lesions. J Cell Sci 2000, 113:2355-2361.
27. Lutgens E., Gijbels M., Smook M., Heeringa P., Gotwals P., Koteliansky V.E., Daemen M.J. Transforming growth factor-beta mediates balance between inflammation and fibrosis during plaque progression. Arterioscler Thromb Vasc Biol 2002, 22:975-982.
28. Ochi H., Abraham M., Ishikawa H., Frenkel D., Yang K., Basso A.S., Wu H., Chen M.L., Gandhi R., Miller A., et al. Oral CD3-specific antibody suppresses autoimmune encephalomyelitis by inducing CD4+ CD25- LAP+ T cells. Nat Med 2006, 12:627-635.
29. Ishikawa H., Ochi H., Chen M.L., Frenkel D., Maron R., Weiner H.L. Inhibition of autoimmune diabetes by oral administration of anti-CD3 monoclonal antibody. Diabetes 2007, 56:2103-2109.
30. Sasaki N., Yamashita T., Takeda M., Shinohara M., Nakajima K., Tawa H., Usui T., Hirata K. Oral anti-CD3 antibody treatment induces regulatory T cells and inhibits the development of atherosclerosis in mice. Circulation 2009, 120:1996-2005.
31. Miossec P., Korn T., Kuchroo V.K. Interleukin-17 and type 17 helper T cells. N Engl J Med 2009, 361:888-898.
32. Bettelli E., Korn T., Oukka M., Kuchroo V.K. Induction and effector functions of T(H)17 cells. Nature 2008, 453:1051-1057.
33. Takatori H., Kanno Y., Watford W.T., Tato C.M., Weiss G., Ivanov I.I., Littman D.R., O'Shea J.J. Lymphoid tissue inducer-like cells are an innate source of IL-17 and IL-22. J Exp Med 2009, 206:35-41.
34. Zhou L., Chong M.M., Littman D.R. Plasticity of CD4+ T cell lineage differentiation. Immunity 2009, 30:646-655.
35. Quintana F.J., Basso A.S., Iglesias A.H., Korn T., Farez M.F., Bettelli E., Caccamo M., Oukka M., Weiner H.L. Control of T(reg) and T(H)17 cell differentiation by the aryl hydrocarbon receptor. Nature 2008, 453:65-71.
36. Zhang F., Meng G., Strober W. Interactions among the transcription factors Runx1, RORgammat and Foxp3 regulate the differentiation of interleukin 17-producing T cells. Nat Immunol 2008, 9:1297-1306.
37. Iwakura Y., Ishigame H. The IL-23/IL-17 axis in inflammation. J Clin Invest 2006, 116:1218-1222.
38. Dong C. TH17 cells in development: an updated view of their molecular identity and genetic programming. Nat Rev Immunol 2008, 8:337-348.
39. Milner J.D., Brenchley J.M., Laurence A., Freeman A.F., Hill B.J., Elias K.M., Kanno Y., Spalding C., Elloumi H.Z., Paulson M.L., et al. Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. Nature 2008, 452:773-776.
40. Puel A., Doffinger R., Natividad A., Chrabieh M., Barcenas-Morales G., Picard C., Cobat A., Ouachee-Chardin M., Toulon A., Bustamante J., et al. Autoantibodies against IL-17A. IL-17F, and IL-22 in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I. J Exp Med 2010, 207:291-297.
41. Kisand K., Boe Wolff A.S., Podkrajsek K.T., Tserel L., Link M., Kisand K.V., Ersvaer E., Perheentupa J., Erichsen M.M., Bratanic N., et al. Chronic mucocutaneous candidiasis in APECED or thymoma patients correlates with autoimmunity to Th17-associated cytokines. J Exp Med 2010, 207:299-308.
42. Kolls J.K., Linden A. Interleukin-17 family members and inflammation. Immunity 2004, 21:467-476.
43. Ruddy M.J., Wong G.C., Liu X.K., Yamamoto H., Kasayama S., Kirkwood K.L., Gaffen S.L. Functional cooperation between interleukin-17 and tumor necrosis factor-alpha is mediated by CCAAT/enhancer-binding protein family members. J Biol Chem 2004, 279:2559-2567.
44. Eid R.E., Rao D.A., Zhou J., Lo S.F., Ranjbaran H., Gallo A., Sokol S.I., Pfau S., Pober J.S., Tellides G. Interleukin-17 and interferon-gamma are produced concomitantly by human coronary artery-infiltrating T cells and act synergistically on vascular smooth muscle cells. Circulation 2009, 119:1424-1432.
45. McGeachy M.J., Bak-Jensen K.S., Chen Y., Tato C.M., Blumenschein W., McClanahan T., Cua D.J. TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology. Nat Immunol 2007, 8:1390-1397.
46. O'Connor W., Kamanaka M., Booth C.J., Town T., Nakae S., Iwakura Y., Kolls J.K., Flavell R.A. A protective function for interleukin 17A in T cell-mediated intestinal inflammation. Nat Immunol 2009, 10:603-609.
47. Schnyder-Candrian S., Togbe D., Couillin I., Mercier I., Brombacher F., Quesniaux V., Fossiez F., Ryffel B., Schnyder B. Interleukin-17 is a negative regulator of established allergic asthma. J Exp Med 2006, 203:2715-2725.
48. Ke Y., Liu K., Huang G.Q., Cui Y., Kaplan H.J., Shao H., Sun D. Anti-inflammatory role of IL-17 in experimental autoimmune uveitis. J Immunol 2009, 182:3183-3190.
49. Chang S.H., Dong C. A novel heterodimeric cytokine consisting of IL-17 and IL-17F regulates inflammatory responses. Cell Res 2007, 17:435-440.
50. Gaffen S.L. Structure and signalling in the IL-17 receptor family. Nat Rev Immunol 2009, 9:556-567.
51. van Es T., van Puijvelde G.H., Ramos O.H., Segers F.M., Joosten L.A., van den Berg W.B., Michon I.M., de Vos P., van Berkel T.J., Kuiper J. Attenuated atherosclerosis upon IL-17R signaling disruption in LDLr deficient mice. Biochem Biophys Res Commun 2009, 388:261-265.
52. Smith E., Stark M.A., Zarbock A., Burcin T.L., Bruce A.C., Vaswani D., Foley P., Ley K. IL-17A inhibits the expansion of IL-17A-producing T cells in mice through " short-loop" inhibition via IL-17 receptor. J Immunol 2008, 181:1357-1364.
53. Erbel C., Chen L., Bea F., Wangler S., Celik S., Lasitschka F., Wang Y., Bockler D., Katus H.A., Dengler T.J. Inhibition of IL-17A attenuates atherosclerotic lesion development in ApoE-deficient mice. J Immunol 2009, 183:8167-8175.
54. Holland S.M., DeLeo F.R., Elloumi H.Z., Hsu A.P., Uzel G., Brodsky N., Freeman A.F., Demidowich A., Davis J., Turner M.L., et al. STAT3 mutations in the hyper-IgE syndrome. N Engl J Med 2007, 357:1608-1619.
55. Taleb S., Romain M., Ramkhelawon B., Uyttenhove C., Pasterkamp G., Herbin O., Esposito B., Perez N., Yasukawa H., Van Snick J., et al. Loss of SOCS3 expression in T cells reveals a regulatory role for interleukin-17 in atherosclerosis. J Exp Med 2009, 206:2067-2077.
56. Kwak B., Mulhaupt F., Myit S., Mach F. Statins as a newly recognized type of immunomodulator. Nat Med 2000, 6:1399-1402.
57. Youssef S., Stuve O., Patarroyo J.C., Ruiz P.J., Radosevich J.L., Hur E.M., Bravo M., Mitchell D.J., Sobel R.A., Steinman L., et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 2002, 420:78-84.
58. George J. Mechanisms of disease: the evolving role of regulatory T cells in atherosclerosis. Nat Clin Pract Cardiovasc Med 2008, 5:531-540.
59. Platten M., Youssef S., Hur E.M., Ho P.P., Han M.H., Lanz T.V., Phillips L.K., Goldstein M.J., Bhat R., Raine C.S., et al. Blocking angiotensin-converting enzyme induces potent regulatory T cells and modulates TH1- and TH17-mediated autoimmunity. Proc Natl Acad Sci U S A 2009, 106:14948-14953.
60. Tao R., de Zoeten E.F., Ozkaynak E., Chen C., Wang L., Porrett P.M., Li B., Turka L.A., Olson E.N., Greene M.I., et al. Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat Med 2007, 13:1299-1307.